Pulmonx Corporation LUNG
Nov 5, 2026, 9:45 AM EST
- YTD
- +26.70%
- 1 year
- +64.71%
- Market cap
- 123.25M
- Revenue (ttm)
- 79.30M
- Profit margin
- -72.01%
- EPS (ttm)
- -1.01
- Shares out
- 39.49M
- Forward P/E
- -3.91
- YTD return
- +26.70%
- 1-year return
- +64.71%
- Volume
- 40.45K
- Avg volume
- 619.70K
- Open
- 2.86
- Previous close
- 2.83
- Day's range
- 2.77 – 2.94
- 52-week range
- 1.13 – 3.25
- Beta
- 0.68
- Analysts
- Buy
- Price target
- 11.92 (+325.6%)
- Earnings date
- Jul 31, 2024
2Y -4.30 (-60.48%)
Key statistics
- Enterprise value
- 190.88M
- PEG ratio
- 0.00
- Price / sales
- 3.12
- Price / book
- 2.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 15.40%
- Free cash flow
- -14.47M
- Total cash
- 107.78M
- Total debt
- 55.81M
- Return on equity
- -51.99%
- Short % of float
- 2.92%
- 50-day average
- 6.51
- 200-day average
- 7.33
Analyst view
Consensus: buy
- Target (low)
- 7.50
- Target (mean)
- 11.92
- Target (high)
- 16.00
- Strong buy1
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Jul 31, 2024
Expected Jul 31, 2024. Consensus EPS estimate -0.44894.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.43 | -0.36 | +0.07 | +16.28% |
| Jul 31, 2024 | Jun 1, 2024 | -0.41 | -0.39 | +0.02 | +4.88% |
| Jul 31, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| May 1, 2024 | Mar 1, 2024 | -0.43 | -0.36 | +0.07 | +16.28% |
| May 1, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| Feb 21, 2024 | Dec 1, 2023 | -0.39 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Dec 11, 2024 | Citigroup | down | Buy | Neutral |
| Oct 31, 2024 | Stifel | main | Buy | Buy |
| Aug 1, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 1, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 1, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
About Pulmonx Corporation
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pulmonx.com
News
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Pulmonx Q3 2026 Earnings Call Transcript - 12 Health Care Stocks Moving In Tuesday's After-Market Session
Pulmonx Q3 EPS $(0.19) Beats $(0.26) Estimate, Sales $22.835M Beat $21.944M Estimate 
Pulmonx Affirms FY2026 Sales Guidance of $90.000M-$92.000M vs $90.608M Est - 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on LUNG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | Director | Stock Award(Grant) | Jun 2, 2024 | 36,246 |
| FERRARI RICHARD M | Director | Stock Award(Grant) | Jun 2, 2024 | 57,871 |
| FLORIN DANIEL P | Director | Stock Award(Grant) | Jun 2, 2024 | 56,757 |
| FRENCH GLENDON E III | Director | Sale | Nov 21, 2024 | 1,071,970 |
| LEHMAN DAVID AARON | General Counsel | Sale | Dec 1, 2024 | 197,851 |
| MEAD DANA G JR | Director | Stock Award(Grant) | Jun 2, 2024 | 66,637 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.87% | 5,872,882 | 36.76M | Sep 29, 2024 |
| Primecap Management Company | 14.37% | 5,676,011 | 35.53M | Sep 29, 2024 |
| Morgan Stanley | 9.60% | 3,788,945 | 23.72M | Sep 29, 2024 |
| Blackrock Inc. | 7.08% | 2,795,561 | 17.50M | Sep 29, 2024 |
| Vanguard Group Inc | 5.77% | 2,278,905 | 14.27M | Sep 29, 2024 |
| Deutsche Bank Aktiengesellschaft | 2.84% | 1,121,840 | 7.02M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Odyssey Aggressive Growth Fund | 9.78% | 3,861,216 | 24.17M | Sep 29, 2024 |
| Fidelity Small Cap Growth Fund | 3.78% | 1,493,472 | 9.35M | Aug 30, 2024 |
| Fidelity Select Portfolios - Pharmaceuticals | 3.63% | 1,431,522 | 8.96M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.94% | 1,161,671 | 7.27M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.48% | 978,930 | 6.13M | Oct 30, 2024 |
| Fidelity Advisor Small Cap Fund | 2.11% | 832,400 | 5.21M | Aug 30, 2024 |